

EN
P-002410/2024
Answer given by Mr Hansen
on behalf of the European Commission
(3.1.2025)

Like with previous EU framework programmes for research and innovation, the Commission continues, under Horizon Europe¹, to fund research to support the control of bluetongue, including the development of vaccines, as appropriate, notably through the co-funded partnership on animal health and welfare². One of its projects aims to develop tools such as vaccine platforms and expression systems, immunological toolboxes and delivery systems. It targets different pathogens including bluetongue viruses and aims to develop and test mRNA³ and DNA⁴ vaccines compatible with a multivalent approach.

As mentioned in reply to written questions E-001819/2024 and E-002019/2024, financial support can be provided under the Common Market Organisation, rural development programmes, Common Agricultural Policy national strategic plans and State aid.

Regulation (EU) 2019/6⁵ establishes the rules for the placing on the market, manufacturing, import, export, supply, distribution, pharmacovigilance, control and use of veterinary medicines. Products authorised at national level can only be marketed in the Member State(s) in which they have been authorised. Only the centralised procedure results in a marketing authorisation valid across the EU. That procedure is mandatory only for certain products; bluetongue vaccines currently available do not fall within its scope. This means that companies can choose which Member States to seek marketing authorisation from and where to market their products.

¹ https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en

² <https://cordis.europa.eu/project/id/101136346> ; <https://www.eupahw.eu/index.html>

³ Messenger ribonucleic acid.

⁴ Deoxyribonucleic acid.

⁵ Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43, ELI: <http://data.europa.eu/eli/reg/2019/6/oj>).